Dogwood Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Dogwood Therapeutics Stock-Based Compensation Growth & History (DWTX)
Dogwood Therapeutics's stock-based compensation was $355,642 for fiscal 2025.
View full Dogwood Therapeutics company overviewDogwood Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $355,642 | −$120,379 | −25.29% |
| 2024 | 2024-12-31 | $476,021 | −$143,951 | −23.22% |
| 2023 | 2023-12-31 | $619,972 | $37,313 | +6.40% |
| 2022 | 2022-12-31 | $582,659 | $259,778 | +80.46% |
| 2021 | 2021-12-31 | $322,881 | −$7.1M | −95.65% |
| 2020 | 2020-12-31 | $7.4M | — | — |
Dogwood Therapeutics quarterly stock-based compensation
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $543,203 | $478,176 | +735.35% |
| Q1 2026 | 2026-03-31 | $449,419 | $364,945 | +432.02% |
| Q4 2025 | 2025-12-31 | $157,860 | $64,058 | +68.29% |
| Q3 2025 | 2025-09-30 | $48,281 | −$46,021 | −48.80% |
| Q2 2025 | 2025-06-30 | $65,027 | −$83,921 | −56.34% |
| Q1 2025 | 2025-03-31 | $84,474 | −$54,495 | −39.21% |
| Q4 2024 | 2024-12-31 | $93,802 | −$54,504 | −36.75% |
| Q3 2024 | 2024-09-30 | $94,302 | −$54,003 | −36.41% |
| Q2 2024 | 2024-06-30 | $148,948 | −$12,716 | −7.87% |
| Q1 2024 | 2024-03-31 | $138,969 | −$22,728 | −14.06% |
| Q4 2023 | 2023-12-31 | $148,306 | −$1,224 | −0.82% |
| Q3 2023 | 2023-09-30 | $148,305 | −$15,961 | −9.72% |
| Q2 2023 | 2023-06-30 | $161,664 | $24,707 | +18.04% |
| Q1 2023 | 2023-03-31 | $161,697 | $29,791 | +22.59% |
| Q4 2022 | 2022-12-31 | $149,530 | $17,624 | +13.36% |
| Q3 2022 | 2022-09-30 | $164,266 | $32,360 | +24.53% |
| Q2 2022 | 2022-06-30 | $136,957 | $102,713 | +299.94% |
| Q1 2022 | 2022-03-31 | $131,906 | $107,081 | +431.34% |
| Q4 2021 | 2021-12-31 | $131,906 | — | — |
| Q3 2021 | 2021-09-30 | $131,906 | −$1.9M | −93.40% |
| Q2 2021 | 2021-06-30 | $34,244 | — | — |
| Q1 2021 | 2021-03-31 | $24,825 | — | — |
| Q3 2020 | 2020-09-30 | $2.0M | — | — |
Dogwood Therapeutics stock-based compensation trends
Over the last five fiscal years, Dogwood Therapeutics's stock-based compensation decreased from $7.4M to $355,642, a change of −$7.1M. The latest reported quarter, Q2 2026, shows $543,203.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dogwood Therapeutics source filings ↗